All studies
Cardiology · EHR · China

Chen 2026

Drug-induced QT prolongation

QBA performedITTSuperiorityAcademia4/5 disclosures
Comparisons
1
In the analysis
1
all comparisons pooled
Target trials
1
Emulations reported
1
2 treatments

Comparisons

1 shown
Randomized trialEmulation
Outcome & target trialTrial vs emulationOn a shared scaleAgreement
Change in Bazett-corrected QT interval after two statin doses
vs Zhu rosuvastatin-atorvastatin QTc trial·MD·Safety
7.403.55–11.3
7.427.15–7.69
overlapPartial alignment0.01 SE apart

Design and methods

Estimand
ITT
Design hypothesis
Superiority
Matching / weighting
1:1 propensity-score matching
Analysis method
Matched linear regression
Missing data
Complete case
DAG
No
QBA
Yes

Data and sample

Data type
EHR
Data sources
4
Geography
China
Eligible sample
98860
Treated
49430
Control
49430
Emulations
1
Treatments compared
2

Transparency

4/5
Protocol
No pre-registration
Preprint
No preprint
Data availability
Available on reasonable request subject to data-use approval
Code availability
Available on reasonable request
Conflicts of interest
Declared: None
Funding
Declared: None

The 0-5 count records which disclosures are present. It is not a quality score: a data link does not establish that the data are reusable.

Provenance

Review key
2026_Chen_QTc
DOI
10.1007/s00228-026-04076-w
Affiliations
Shanghai Sixth People's Hospital and participating Chinese hospitals
Sector
Academia
Target trials (study level)
Zhu rosuvastatin-atorvastatin QTc trial